In this article, we will take a look at the Top 10 Robotics Stocks to Buy According to Analysts.
Markets and Markets research projects that the industrial robotics market will develop at a compound annual growth rate (CAGR) of 14% from $17 billion in 2024 to $35 billion by 2030. Moreover, a number of experts believe that the robotics sector will revolutionize the manufacturing, healthcare, and logistics industries beyond 2030 as robots start to function more autonomously.
While most modern robots look like computer-driven industrial machines, there have been advancements in humanoid robot technology in recent years. According to Morgan Stanley, there will be 40,000 humanoid robots by 2030, and by 2050, that number will exceed 63 million. Adam Jonas, a managing director at the firm, believes humanoid robots to be a multi-decade, trillion-dollar opportunity as the adoption could accelerate when it comes to self-driving vehicles.
Our Methodology
We first sifted through a number of online sources to compile a list of the top robotics stocks. We then selected the 10 stocks with an upside potential of over 15% as of August 16. These stocks are ranked in ascending order based on their average share price upside potential, as of August 16. Additionally, we have mentioned the hedge fund sentiment around each stock, as of Q1 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. Deere & Company (NYSE:DE)
Analyst Upside: 15.96%
Number of Hedge Fund Holders: 53
Deere & Company (NYSE:DE) ranks among the top robotics to buy according to analysts. Following the company’s fiscal third-quarter results, Oppenheimer maintained its Outperform rating on Deere & Company (NYSE:DE) and increased its price target from $560 to $566 on August 15.
The change follows a 6.8% stock selloff sparked by Deere’s quarterly report, which Oppenheimer described as offering investors an alluring entry position as positive signals appear in the markets of Europe and Latin America.
Although the end-of-period results were characterized as “anticipated and better-than-feared,” Oppenheimer pointed out that pessimistic comments to the report were centered on poor end-of-period results, unanticipated negative pricing in Large Agriculture, and increasing tariff expenses.
With projections of modest increase led by North American harvest results, clarity on biofuels policy, and performance in used equipment merchandising, the firm maintained expectations at the higher range of the 2026 consensus.
Deere & Company (NYSE:DE) is an American company that manufactures agricultural, heavy, and forestry machinery, diesel engines, heavy equipment drivetrains, and lawn care equipment. The company also provides financial services and engages in other business operations. With its AI-powered autonomous tractors, harvesters, sprayers, and other machinery, the company has began venturing into agricultural robotics. One notable instance is the company’s See and Spray robots, which are used to spray herbicides and fertilizers.
9. TechnipFMC (NYSE:FTI)
Analyst Upside: 18.82%
Number of Hedge Fund Holders: 58
TechnipFMC (NYSE:FTI) ranks among the top robotics to buy according to analysts. Bernstein analyst Guillaume Delaby maintained his Market Perform rating on TechnipFMC (NYSE:FTI) and increased his price target from $32 to $37 on July 29. The price target rise comes after TechnipFMC’s impressive second-quarter 2025 results, which showed $2,535 million in revenue and $509 million in EBITDA.
Bernstein increased TechnipFMC’s 2025–2028 EBITDA projections by 3%, 6%, 6%, and 15%, respectively, citing the company’s optimism about landing an extra $10 billion in subsea orders in 2026.
In addition to highlighting TechnipFMC’s “increasing uniqueness” in the market and its multi-year visibility in the subsea segment, the analyst pointed out that the legacy company traded at a peak multiple of roughly 12x EV/EBITDA during the 2011–2013 upcycle.
TechnipFMC (NYSE:FTI) focuses on energy projects, technologies, systems, and services businesses. The company operates through two segments: Subsea and Surface Technologies. Through its Schilling Robotics business, TechnipFMC is making progress toward more autonomous underwater operations. The company’s ROVs are used in deepwater research, the oil and gas industry, the renewable energy sector, and military applications across the world.
8. Boston Scientific Corporation (NYSE:BSX)
Analyst Upside: 20.10%
Number of Hedge Fund Holders: 108
Boston Scientific Corporation (NYSE:BSX) ranks among the top robotics to buy according to analysts. Mizuho kept its Outperform rating on Boston Scientific Corporation (NYSE:BSX), and increased its price target for the medical device maker from $130 to $140 on July 24.
The firm reported that the global recall of the ACURATE transcatheter aortic valve replacement (TAVR) system in the second half of the year was expected to be compensated by solid performance in Boston Scientific’s FARAPULSE and WATCHMAN product lines.
While Boston Scientific Corporation (NYSE:BSX) has no plans to re-engineer the ACURATE valve, putting it “at square one in the TAVR space,” the company is still on track to acquire clearances for FARAPULSE in China and Japan before the end of the year, according to Mizuho’s research.
Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters. A leading name in robotics, the company has made great strides in the humanoid aspect of the industry with its two-legged Atlas robot.
7. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Analyst Upside: 26.37%
Number of Hedge Fund Holders: 106
Intuitive Surgical, Inc. (NASDAQ:ISRG) ranks among the top robotics to buy according to analysts. As the company’s da Vinci (EPA:SGEF) 5 surgical system moves into its global launch phase, Bernstein SocGen Group maintained its Outperform rating on Intuitive Surgical, Inc. (NASDAQ:ISRG) and increased its price target from $675 to $685 on July 23.
With revenue of $2.44 billion, the company reported impressive second-quarter earnings, outpacing consensus projections by 4% and indicating 21% growth. Even though worldwide da Vinci systems placements missed estimates by 4%, adjusted earnings per share increased by 23% to $2.19.
During the quarter, Intuitive Surgical’s da Vinci 5 placements increased to 180 units, up from 147 in the first quarter, and procedures gained 17% globally, which was slightly higher than the consensus estimate. In the United States, Intuitive Surgical, Inc. (NASDAQ:ISRG) is moving from a limited to a broad launch after da Vinci 5 was approved in March 2024. This will let clients to upgrade their current fleets to the new system.
Intuitive Surgical, Inc. (NASDAQ:ISRG) is dedicated to developing, manufacturing, and marketing robotic products that utilize minimally invasive surgery to improve clinical outcomes for patients.
6. EPAM Systems, Inc. (NYSE:EPAM)
Analyst Upside: 30.95%
Number of Hedge Fund Holders: 46
EPAM Systems, Inc. (NYSE:EPAM) ranks among the top robotics to buy according to analysts. Mizuho kept its Outperform rating on EPAM Systems, Inc. (NYSE:EPAM) and increased its price target from $224 to $225 on August 12. The update followed EPAM’s impressive second-quarter 2025 performance and the company’s decision to increase the low end of its 2025 organic constant currency forecast from +2% to +5% to +3% to +5%.
According to Mizuho, there are two main reasons for EPAM’s rapid organic growth: a resurgence in client interest in the company’s services due to generative AI, and EPAM’s isolation from several troubled end markets and services that have impacted rivals.
Mizuho has also shown confidence in EPAM’s ability to accelerate organic revenue growth in the medium term by slightly increasing its 2025 and 2026 revenue and EPS projections.
EPAM Systems, Inc. (NYSE:EPAM) is a multinational consulting, software development, and digital engineering company that offers all-inclusive solutions that involve product design, cloud services, digital transformation strategy, platform engineering, and custom software development. The company develops, engineers, and optimizes intelligent automation solutions, such as robotic process automation tools, in collaboration with its global clients.
5. UiPath Inc. (NYSE:PATH)
Analyst Upside: 31.78%
Number of Hedge Fund Holders: 41
UiPath Inc. (NYSE:PATH) ranks among the top robotics to buy according to analysts. In line with its cautious approach toward the company, Truist Securities reaffirmed its Hold rating and $13 price target on UiPath Inc. (NYSE:PATH) on July 15. Analyst Terry Tillman adjusted the quarterly estimates for fiscal year 2026, lowered the second-quarter free cash flow expectations since they were “likely too aggressive post strong 1Q performance and in relation to Street.”
Additionally, citing likely mis-modeling between the two periods, Truist shifted its forecasts of subscription service revenue from the third quarter to the fourth quarter.
Truist’s primary projections for fiscal year 2026, such as total revenue, annualized renewal run-rate, non-GAAP operating income, and free cash flow, are still in line with company guidance and consensus Street expectations despite these changes.
The firm stated that UiPath Inc. (NYSE:PATH) is “making aggressive moves with its combination of automation robots, AI agents and orchestration in a single agnostic platform emphasizing security and governance.”
UiPath Inc. (NYSE:PATH) is a multinational software company specializing in robotic process automation (RPA). The company automates manual procedures by providing a workflow designer, recording capabilities, and visual programming tools. UIPath’s RPA facilitates the development, deployment, and control of software robots that mimic human behavior.
4. Richtech Robotics Inc. (NASDAQ:RR)
Analyst Upside: 43.81%
Number of Hedge Fund Holders: 7
Richtech Robotics Inc. (NASDAQ:RR) ranks among the top robotics to buy according to analysts. Through its Chinese joint venture, Richtech Robotics Inc. (NASDAQ:RR) reported at the end of June that it had reached a sales agreement with Beijing Tongchuang Technology Development Co., Ltd. worth more than $4 million.
The contract covers the acquisition, maintenance, and software licensing of products from Richtech’s ADAM, Scorpion, and Titan product lines. With analysts forecasting 33% rise in revenues for the fiscal year, the purchase is anticipated to boost the company’s fourth-quarter revenue and create recurring revenue moving forward.
According to a press release from the company, the new collaboration increases Richtech Robotics’ footprint in China and could lead to new prospects throughout the Asian market.
Richtech Robotics Inc. (NASDAQ:RR) specializes in interactive robotic solutions for the service sector, with additional applications in the healthcare and hotel industries.
3. Serve Robotics Inc. (NASDAQ:SERV)
Analyst Upside: 65.32%
Number of Hedge Fund Holders: N/A
Serve Robotics Inc. (NASDAQ:SERV) ranks among the top robotics to buy according to analysts. Cantor Fitzgerald reaffirmed its Overweight rating and $17 price target for Serve Robotics Inc. (NASDAQ:SERV) on August 12 due to the company’s strong unit economics and key alliances. The firm emphasized that in the second quarter, Serve Robotics deployed 120 robots, increasing its fleet size to 400 units. The fleet size would double in the third quarter, and management reaffirmed its intentions to deploy about 2,000 robots by year’s end.
This month, Serve Robotics Inc. (NASDAQ:SERV) intends to begin operations in Chicago, extending its reach even farther. The company continues to capitalize on its alliance with Uber Eats, which is both its biggest client and its biggest investor, owning about an 8% stake.
Serve Robotics Inc. (NASDAQ:SERV) also benefits from a manufacturing partnership with Magna that permits a low-capital expenditure strategy, according to Cantor Fitzgerald. The firm anticipates Serve to offer a more affordable long-term per-delivery fee than the typical courier fare, which is about $8.
With an emphasis on food delivery in the US, Serve Robotics Inc. (NASDAQ:SERV) designs and develops autonomous, low-emission, sidewalk delivery robots. In 2021, the company split from Uber to become a separate company.
2. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Analyst Upside: 66.45%
Number of Hedge Fund Holders: 27
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the top robotics to buy according to analysts. On August 7, Wells Fargo maintained its Overweight rating on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) but reduced its price target from $75 to $58. The change follows management’s announcement that it no longer anticipates any system replacements in the second half of 2025, reversing earlier projections of roughly 10 replacements this year.
Given that the majority of its installed base is only three years old, Wells Fargo pointed out that PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has overstated the need for replacements, even though the company forecasts system life to be five to seven years.
The firm currently projects 10 replacements at an average selling price of $350,000 for 2026 and expects PROCEPT BioRobotics Corporation (NASDAQ:PRCT) management to discuss its replacements and trade-in strategy when delivering guidance for the upcoming year.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage company that focuses on urology surgical robotics systems. The company’s flagship product, the AquaBeam Robotic System, is a cutting-edge image-guided device intended for minimally invasive urologic procedures.
1. Accuray Incorporated (NASDAQ:ARAY)
Analyst Upside: 208.22%
Number of Hedge Fund Holders: 16
Accuray Incorporated (NASDAQ:ARAY) ranks among the top robotics to buy according to analysts. After Accuray Incorporated (NASDAQ:ARAY) reported fiscal fourth-quarter results and fiscal 2026 outlook, BTIG maintained its Buy rating on the radiation therapy company and increased its price target from $4 to $5 on August 14.
Accuray’s fiscal fourth-quarter revenue of $127.5 million exceeded consensus projections of $123.8 million, despite a 5% year-over-year decline. Product revenue of $70.7 million, which was over $4 million higher than the forecast, was the main driver of the sales beat, while services revenue of $56.8 million remained as expected.
According to BTIG, Accuray Incorporated (NASDAQ:ARAY) overcame several obstacles during the quarter, such as the temporary suspension of shipments to China and the disruptions caused by Middle East hostilities in the EIMEA region. The firm thinks management has a realistic outlook for fiscal 2026, with room for improvement if macroeconomic headwinds and the tariff situation with China improve.
Accuray Incorporated (NASDAQ:ARAY) that is involved in developing cutting-edge cancer and neuro-radiosurgery solutions. The CyberKnife technology, which treats primary and metastatic malignancies outside the brain, is the company’s most well-known robotic stereotactic radiosurgery and stereotactic body radiation therapy technology.
While we acknowledge the potential of ARAY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARAY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
